Inhibition of factor XIIa, a new approach in management of thrombosis.
Inhibition of factor XIIa, a new approach in management of thrombosis.
复制标题
DOI：
10.3978/j.issn.2305-5839.2015.02.14
复制
发表时间：
2015-04
影响因子：
--
通讯作者：
A. Dorgalaleh;M. Hosseini;R. N. Mobaraki;S. Alizadeh;S. Hosseini;S. Tabibian;M. Shamsizadeh;Esmaeil Sanei Moghaddam;S. Khosravi;Aziz Rahimizadeh
中科院分区：
文献类型：
--
作者：
A. Dorgalaleh;M. Hosseini;R. N. Mobaraki;S. Alizadeh;S. Hosseini;S. Tabibian;M. Shamsizadeh;Esmaeil Sanei Moghaddam;S. Khosravi;Aziz Rahimizadeh
血栓形成是可能发生在动脉或静脉中的血凝块形成的不利条件。虽然动脉和静脉血栓形成的内容和机制不同，但这两种情况对社区健康都有很大的影响，并具有显著的临床后果。静脉血栓形成与凝血级联反应的不适当激活有关，并且具有高纤维蛋白含量和低血小板，而血小板的激活在动脉血栓形成中起主要作用。到目前为止，已经做出了一些努力来解决这种病理状况或至少使患者中血栓形成的死亡率和发病率最小化。许多抗凝剂已被开发出不同的临床应用。速效抗凝剂如肝素通常用于血栓栓塞的初始治疗，而慢效维生素K拮抗剂主要用于长期治疗。
Thrombosis is an unfavorable condition of blood clot formation that may happen in arteries or veins. Although arterial and venous thromboses are different in content and mechanism of formation, both conditions have a large impact on community health with significant clinical consequences. Venous thrombosis is associated with inappropriate activation of coagulation cascade, and has high fibrin content and low platelets, whereas activation of platelets plays a major role in arterial thrombosis. Several efforts have been made so far to resolve this pathological condition or at least minimize the mortality and morbidity of thrombosis in patients. Many anticoagulants have been developed with different clinical applications. Immediate acting anticoagulants like heparin are commonly used for initial treatment of thromboembolism while slower acting vitamin K antagonists are largely used for long term therapy.